➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Johnson and Johnson

Last Updated: September 28, 2021

DrugPatentWatch Database Preview

Investigational Drug Information for Bucillamine

Email this page to a colleague

« Back to Dashboard

What is the development status for investigational drug Bucillamine?

Bucillamine is an investigational drug.

There have been 5 clinical trials for Bucillamine. The most recent clinical trial was a Phase 3 trial, which was initiated on January 1st 2007.

The most common disease conditions in clinical trials are Arthritis, Arthritis, Rheumatoid, and Cystinuria. The leading clinical trial sponsors are Revive Therapeutics, Ltd., Keio University, and Sanofi.

Recent Clinical Trials for Bucillamine
Bucillamine in Treatment of Patients With COVID-19Revive Therapeutics, Ltd.Phase 3
Trial in Patients With CystinuriaRevive Therapeutics, Ltd.Phase 2
Bucillamine for the Treatment of Acute Gout Flare in Subjects With Moderate to Severe GoutRevive Therapeutics, Ltd.Phase 2

See all Bucillamine clinical trials

Clinical Trial Summary for Bucillamine

Top disease conditions for Bucillamine
Top clinical trial sponsors for Bucillamine

See all Bucillamine clinical trials

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.